CELLECTAR BIOSCIENCES

Investor Factsheet | Q1 2023

OVERVIEW

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and the company plans to develop PDCs independently and through research and development collaborations.

Iopofosine I 131 (CLR 131) and PDC PLATFORM

Iopofosine is a PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. This novel, targeted radiotherapeutic provides a differentiated product profile with unique benefits. Ongoing clinical studies include:

- The pivotal Phase 2 Part B (CLOVER-WaM): A registration study currently evaluating iopofosine in Waldenstrom's macroglobulinemia (WM) patients who have received at least 2 prior lines of therapy, including in Bruton tyrosine kinase inhibitor (BTKi) failed or suboptimal-response patients.
- The Phase 2 Part A (CLOVER-1): Additional evaluation of iopofosine in highly refractory multiple myeloma patients and select B-cell malignancies.
- A Phase 1 dose-escalating pediatric clinical study in children and adolescents with relapsed or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin's lymphoma). The study is being conducted internationally at seven leading pediatric cancer centers.
- A proprietary PDC chemotherapeutic program and partnered assets including an alpha emitter and small molecule cytotoxic compounds.

FAST FACTS (as of 9/30/2022) [1, 2]

Ticker (Exchange)	CLRB (Nasdaq)
Stock Price[2]	$1.85
Market Cap	$17.4M
Cash Available[1]	$17.8M
Outstanding Shares[2]	9.4M
52-Week Range[2]	$1.25 - $7.90
Avg. Daily Volume[2]	59,800 (3 mo.)
Headquarters	Florham Park,NJ
Fiscal Year End	December 31

1. As reported 9/30/2022
2. As of 1/6/2023

CURRENT PIPELINE OPPORTUNITIES & DEVELOPMENT STATUS



Investor Factsheet | Q1 2023

LEAD THERAPEUTIC CANDIDATE: Iopofosine I 131 (CLR 131)

Iopofosine is a radio-labeled small molecule therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Iopofosine is currently in four ongoing clinical studies evaluating its safety and efficacy in a variety of hematologic and solid cancers. A pivotal study in 50 patients with WM who have received at least 2 prior lines of therapy, including those that have failed or had a suboptimal response to BTKi therapy, was initiated in January 2021. To date, iopofosine has demonstrated a 100% overall response rate in WM patients in Part A of the Phase 2 study.

PDC PLATFORM

Our PDC Platform provides selective delivery of a diverse range of oncologic molecules to cancer cells – whether it's the primary tumor, metastatic tumor and/or cancer stem cells. Due to the diversity of molecules that can be used, PDCs can treat a wide variety of cancers: both hematologic and solid tumors, including brain tumors.

- The PDC platform's mechanism of entry does not rely upon specific cell surface epitopes or antigens like other targeted delivery platforms, allowing the molecules to potentially target all existing tumor cells in the body.
- Our PDC platform takes advantage of a metabolic pathway utilized by all tumor cell types in all stages of the tumor cycle. Tumor cells modify regions on the cell surface as a result of the utilization of this metabolic pathway. Our PDCs bind to these regions and enter the intracellular compartment.
- The PDC platform has the capacity to link with almost any molecule and provide a significant increase in targeted oncologic payload delivery to potentially all tumor cells in the body. As a result, it improves the therapeutic index of oncologic drug payloads, enhancing or maintaining efficacy while reducing adverse events.

RECENT DEVELOPMENTS

November 30, 2022

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

November 21, 2022

Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

November 16, 2022

Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

November 3, 2022

Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update

MANAGEMENT TEAM

James Caruso
President, CEO and Director

Chad Kolean
Chief Financial Officer

Shane Lea
Chief Commercial Officer

Jarrod Longcor
Chief Operating Officer

CONTACT

Cellectar Biosciences, Inc.

100 Campus Drive, Suite 207
Florham Park, NJ 07932

P: (608) 441-8120

investors@cellectar.com